Kalaris Therapeutics Stock Price, News & Analysis
KLRS
NASDAQ
Company Description
Welcome to the overview page for Kalaris Therapeutics (KLRS), where you can find comprehensive stock information and company updates.
Explore the latest news on strategic partnerships, quarterly and annual financial results, and regulatory filings including SEC reports and insider transactions.
Visualize performance trends using the interactive price chart, and keep track of upcoming events such as earnings calls, dividend dates, and investor conferences.
Stock Performance
$2.37
+4.41%
+0.10
Last updated: August 15, 2025 at 10:25
-75.68 %
Performance 1 year
$46.6M
Market Cap
18.7M
Shares outstanding
Latest News
SEC Filings
Financial Highlights
$0
Revenue (TTM)
-$10,196,000
Net Income (TTM)
-$2.52
Diluted EPS (TTM)
-$7,441,000
Operating Cash Flow
14.31
Current Ratio
-$10,354,000
Operating Income
Upcoming Events
October 1, 2025 - December 31, 2025
Initial clinical data release
Release of initial clinical data from TH103 Phase 1 trial
October 1, 2025
Initial clinical data release
Frequently Asked Questions
What is the current stock price of Kalaris Therapeutics (KLRS)?
The current stock price of Kalaris Therapeutics (KLRS) is $2.27 as of August 14, 2025.
What is the market cap of Kalaris Therapeutics (KLRS)?
The market cap of Kalaris Therapeutics (KLRS) is approximately 46.6M.
What is the revenue (TTM) of Kalaris Therapeutics (KLRS) stock?
The trailing twelve months (TTM) revenue of Kalaris Therapeutics (KLRS) is $0.
What is the net income of Kalaris Therapeutics (KLRS)?
The trailing twelve months (TTM) net income of Kalaris Therapeutics (KLRS) is -$10,196,000.
What is the earnings per share (EPS) of Kalaris Therapeutics (KLRS)?
The diluted earnings per share (EPS) of Kalaris Therapeutics (KLRS) is -$2.52 on a trailing twelve months (TTM) basis.
What is the operating cash flow of Kalaris Therapeutics (KLRS)?
The operating cash flow of Kalaris Therapeutics (KLRS) is -$7,441,000.
What is the current ratio of Kalaris Therapeutics (KLRS)?
The current ratio of Kalaris Therapeutics (KLRS) is 14.31, indicating the company's ability to pay short-term obligations.
What is the operating income of Kalaris Therapeutics (KLRS)?
The operating income of Kalaris Therapeutics (KLRS) is -$10,354,000.